Travaux scientifiques

Prof. Dr. Yelda Varol

102 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Validation and Reliability Assessment of the Test of Adherence to Inhalers (TAI) in Turkish Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Thoracic research and practice, 2026

    DOI 10.4274/thoracrespract.2026.2026-1-5 PMID 41979103 Texte intégral en libre accèsSource : OpenAlex

  2. Inhaler-specific drug therapy problems in COPD

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa2577 Source : OpenAlex

  3. Polypharmacy in COPD and Its Impact on Clinical Outcomes

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa5825 Source : OpenAlex

  4. Predictors of 90-Day Mortality and the Association of Reperfusion Therapy with 90-Day Mortality in Intermediate-High and High-Risk Pulmonary Embolism: A Real-World Multidisciplinary Cohort Study

    Life, 2026

    DOI 10.3390/life16071189 PMID 42514256 Texte intégral en libre accèsSource : ORCID

  5. Rare Interstitial Lung Diseases in the Elderly: A Different Spectrum?

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa3089 Source : OpenAlex

  6. Clinical heterogeneity and progression risk in pulmonary alveolar microlithiasis: a multicenter real-world cohort

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa891 Source : OpenAlex

  7. Lymphangioleiomyomatosis in Türkiye: Real-World Data from the TRILD Registry

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa5268 Source : OpenAlex

  8. Sex Differences in Clinical Presentation and Outcomes in Acute Pulmonary Embolism: A Nationwide Multicenter Study

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa1376 Source : OpenAlex

  9. B67-20 Thrombolysis and 90-Day Mortality in High- And Intermediate-High-Risk Pulmonary Embolism: A Real-World Cohort Study

    American Journal of Respiratory and Critical Care Medicine, 2026

    DOI 10.1093/ajrccm/aamag162.5721 Source : OpenAlex

  10. Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism

    International Journal of Molecular Sciences, 2026

    DOI 10.3390/ijms27020758 PMID 41596405 Texte intégral en libre accèsSource : ORCID

  11. Late-Onset Nivolumab-Induced Pneumonitis in Metastatic Lung Adenocarcinoma: A Case Report

    Journal of İzmir Chest Hospital, 2026

    DOI 10.14744/igh.2026.06977 Texte intégral en libre accèsSource : OpenAlex

  12. Multidimensional Geriatric Assessment Improves Risk Stratification Beyond Conventional Pneumonia Severity Scores

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa2898 Source : OpenAlex

  13. Dupilumab after sequential omalizumab and benralizumab failure in T2-high asthma–COPD overlap: A case report

    Allergologia et Immunopathologia, 2026

    DOI 10.15586/aei.v54i3.1566 PMID 42115803 Texte intégral en libre accèsSource : ORCID

  14. Survival and mortality risk factors in chronic obstructive pulmonary disease: A three-year cohort analysis

    Eurasian Journal of Pulmonology, 2026

    DOI 10.14744/ejp.2025.56336 Texte intégral en libre accèsSource : OpenAlex

  15. The RATAB Framework: An Interpretable AI-Driven Radiographic Risk Stratification Model for Suspected Lung Lesions

    Journal of Imaging Informatics in Medicine, 2026

    DOI 10.1007/s10278-026-02303-5 PMID 42768277 Source : OpenAlex

  16. Validation Study of Rome Criteria for Assessing COPD Exacerbation Severity and Predicting Clinical Outcomes: Turkish Thoracic Society COPD Assembly

    International Journal of COPD, 2025

    DOI 10.2147/copd.s554744 PMID 41399649 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. Impact of COVID-19 and lockdown on outcomes of COPD patients in Turkey: lessons for the future

    BMC Pulmonary Medicine, 2025

    DOI 10.1186/s12890-025-03883-8 PMID 40885974 Texte intégral en libre accèsSource : OpenAlex

  18. Validation Study of Rome Criteria for Assessing COPD Exacerbation Severity and Predicting Clinical Outcomes:TTS-COPD Assembly

    European Respiratory Journal, 2025

    DOI 10.1183/13993003.congress-2025.pa3627 Source : OpenAlex

  19. Inhaler Technique and Medication Adherence in COPD: Insights from a Nationwide Multicentre Study

    Research Square, 2025

    DOI 10.21203/rs.3.rs-8302012/v1 Texte intégral en libre accèsSource : OpenAlex

  20. The Link Between Outpatient Pulmonary Rehabilitation and Mortality in Symptomatic COPD Patients: Is PR a possibility in reducing mortality?

    İzmir Tıp Fakültesi Dergisi, 2025

    DOI 10.57221/izmirtip.1747163 Texte intégral en libre accèsSource : OpenAlex

  21. Suda Boğulma Tehlikesi Atlatan Hastalarda Etiyolojik Değerlendirme: Nadir Pulmoner Nedenler Eşliğinde Olgu Serisi

    İzmir Tıp Fakültesi Dergisi, 2025

    DOI 10.57221/izmirtip.1748204 Texte intégral en libre accèsSource : OpenAlex

  22. Etiological Evaluation in Patients Nearly Drowning: A Case Series with Rare Pulmonary Causes

    DergiPark (Istanbul University), 2025

    Source : OpenAlex

  23. GeneXpert MTB/RIF and GeneXpert MTB/RIF ultra in tuberculosis diagnosis: A comparative evaluation

    Tuberk Toraks, 2025

    DOI 10.5578/tt.2025021052 PMID 40497809 Texte intégral en libre accèsSource : ORCID

  24. Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: data from the EARCO international registry

    BMC Pulmonary Medicine, 2025

    DOI 10.1186/s12890-025-03782-y PMID 40616025 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  25. The impact of dysnatremia and dyskalemia on mortality and morbidity in COPD patients hospitalized for exacerbations

    Trace Elements and Electrolytes, 2025

    DOI 10.5414/te500081 1 citation (OpenAlex) Source : OpenAlex

  26. Serum endocan levels in COPD patients with frequent exacerbations compared to non-frequent exacerbators

    European Respiratory Journal, 2025

    DOI 10.1183/13993003.congress-2025.pa2513 Source : OpenAlex

  27. Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: data from the EARCO international registry

    Zurich Open Repository and Archive (University of Zurich), 2025

    DOI 10.5167/uzh-281784 Texte intégral en libre accèsSource : OpenAlex

  28. Readmission rates within the first 30 and 90 days after severe COPD exacerbations (RACE study)

    Medicine, 2024

    DOI 10.1097/md.0000000000040483 PMID 39612431 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  29. Risk factors for prolonged hospitalization as a marker for difficult-to-manage exacerbations of chronic obstructive lung disease (COPD): the DiMECO Study

    BMC Pulmonary Medicine, 2024

    DOI 10.1186/s12890-024-03399-7 PMID 39609669 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Factors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly

    Thoracic research and practice, 2024

    DOI 10.5152/thoracrespract.2024.23065 PMID 39115297 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Rate of critical errors in inhaler device use in COPD and associated factors with poor inhaler technique: a multicenter study

    European Respiratory Journal, 2024

    DOI 10.1183/13993003.congress-2024.pa2127 Source : OpenAlex

  32. Obstructive sleep apnea and mortality, response to the letter

    Sleep and Breathing, 2024

    DOI 10.1007/s11325-024-03061-w PMID 38861132 Texte intégral en libre accèsSource : ORCID

  33. Apnea-hypopnea index and the polysomnographic risk factors for predicting 5- to 8-year mortality in patients with OSA

    Sleep and Breathing, 2024

    DOI 10.1007/s11325-023-02868-3 PMID 37422579 6 citations (Europe PMC) Source : ORCID

  34. Effect of peak inspiratory flow rate guided inhaler device selection on the number of COPD exacerbation in the 90 days after discharge

    European Respiratory Journal, 2024

    DOI 10.1183/13993003.congress-2024.pa2117 Source : OpenAlex

  35. The Role of Gender Regarding the Outcomes of Pulmonary Rehabilitation in Patients with COPD: A Retrospective Study

    Journal of Basic and Clinical Health Sciences, 2023

    DOI 10.30621/jbachs.1031419 Texte intégral en libre accèsSource : ORCID

  36. Using Sociodemographic and Clinical Characteristics to Distinguish Between Drug-sensitive and Drug-resistant Tuberculosis

    Forbes Journal of Medicine, 2023

    DOI 10.4274/forbes.galenos.2022.58672 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  37. Suicide Risk Burnout and Risky Alcohol Use Among Physicians

    Forbes Journal of Medicine, 2023

    DOI 10.4274/forbes.galenos.2023.83702 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  38. Treatment Results of Multidrug-Resistant Tuberculosis Patients in the Aegean Region

    Thoracic research and practice, 2023

    DOI 10.5152/thoracrespract.2023.22087 PMID 37503647 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  39. The impact of blood eosinophil levels on in-hospital mortality in a large cohort of 960 hospitalized AECOPD patients

    European Respiratory Journal, 2023

    DOI 10.1183/13993003.congress-2023.oa4930 Source : OpenAlex

  40. Attitude and Practice Toward Use of Cigarettes and Electronic Cigarettes Among Pregnant Women: A Questionnaire-Based Survey

    Turkish Thoracic Journal, 2022

    DOI 10.5152/turkthoracj.2022.22078 PMID 36148528 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  41. RESEARCH BURDEN OF INTERSTITIAL LUNG DISEASES IN TURKEY – RBILD

    Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022

    DOI 10.36141/svdld.v39i1.12269 PMID 35494165 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  42. Prognosis and treatment of COVID-19 infection while receiving treatment for comorbid active tuberculosis: report of two cases

    Mucosa, 2022

    DOI 10.33204/mucosa.1115584 Texte intégral en libre accèsSource : ORCID

  43. 2021 Guideline for the Management of COPD Exacerbations

    Turkish Journal of Emergency Medicine, 2021

    DOI 10.4103/2452-2473.329630 PMID 34849428 19 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  44. COVID-19 phobia in healthcare workers; a cross-sectional study from a pandemic hospital

    Tuberkuloz ve Toraks, 2021

    DOI 10.5578/tt.20219810 PMID 34256511 24 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  45. Which scoring system is better in association with exercise capacity and health status in noncystic fibrosis bronchiectasis patients?

    Turkish journal of medical sciences, 2021

    DOI 10.3906/sag-2005-18 PMID 33081435 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  46. The impact of charlson comorbidity index on mortality from SARS‐CoV‐2 virus infection and A novel COVID‐19 mortality index: CoLACD

    International Journal of Clinical Practice, 2021

    DOI 10.1111/ijcp.13858 PMID 33237615 36 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  47. Characteristics of COVID-19 Pneumonia Cases Treated with Favipiravir in the Chest Diseases Clinic

    Journal of İzmir Chest Hospital, 2021

    DOI 10.5222/igh.2021.47965 Source : OpenAlex

  48. Treatment Results of Multidrug Resistant Tuberculosis (MDR-TB) Patients in the Aegean Region

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa3348 Source : OpenAlex

  49. The Impact of Conjugated Pneumococcal Vaccine on Exacerbation Frequency in Patients with COPD

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa2139 Source : OpenAlex

  50. AHI and the polysomnographic risk factors for predicting 5 to 8 years mortality in patients with OSA

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa2490 Source : OpenAlex